XML 108 R88.htm IDEA: XBRL DOCUMENT v3.25.4
Stock-Based Compensation - Performance Shares Activity (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]        
Unrecognized stock-based compensation cost $ 17.2      
Unrecognized stock-based compensation cost, weighted-average period recognized 1 year 7 months 6 days      
Performance shares        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]        
Unrecognized stock-based compensation cost $ 9.4      
Unrecognized stock-based compensation cost, weighted-average period recognized 1 year 10 months 24 days      
Shares outstanding (in shares) 4,762,440 4,641,512 3,159,910 2,574,537
Shares outstanding, Weighted Average Grant Date Fair Value (in dollars per share) $ 4.63 $ 3.24 $ 4.52 $ 5.26
Restricted stock 1,191,381 2,076,818 1,816,429  
Grant date fair value of restricted stock $ 9.79 $ 2.85 $ 3.16  
Vested (in shares) (580,360) (379,402) (566,891)  
Vested (in dollars per share) $ 4.38 $ 8.30 $ 4.00  
Canceled/Forfeited (in shares) (490,093) (215,814) (664,165)  
Canceled/Forfeited (in dollars per share) $ 4.26 $ 8.55 $ 4.32  
2020 Award | Performance shares        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]        
Restricted stock 77,826   26,200  
Canceled/Forfeited (in shares) (490,093)   (468,393)  
2021 Award | Performance shares        
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]        
Restricted stock   22,351    
Canceled/Forfeited (in shares)   (187,809)